Efficient genetic modification of murine dendritic cells by electroporation with mRNA

Cancer Gene Therapy

Volumn 9, Issue 9, 2002, Pages 787-797

  Van Meirvenne, Sonja ^a   Straetman, Lieven ^a   Heirman, Carlo ^a   Dullaers, Melissa ^a   De Greef, Catherine ^a   Van Tendeloo, Viggo ^b   Thielemans, Kris ^a  

^a FACULTY OF MEDICINE AND PHARMACY   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Antigen presentation; Cancer vaccine; Dendritic cells; mRNA electroporation

Indexed keywords

GREEN FLUORESCENT PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; NERVE GROWTH FACTOR RECEPTOR; OVALBUMIN; TUMOR ANTIGEN; PEPTIDE FRAGMENT; PHOTOPROTEIN; PRIMER DNA; UBIQUITIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; CANCER IMMUNOTHERAPY; CHIMERA; CONTROLLED STUDY; DENDRITIC CELL; DNA MODIFICATION; DOSE RESPONSE; ELECTROPORATION; FEMALE; FLUORESCENCE; GENE EXPRESSION; GENETIC TRANSFECTION; INTERMETHOD COMPARISON; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; ANTIGEN PRESENTATION; C57BL MOUSE; CELL DIVISION; CHEMISTRY; CHICKEN; COMPARATIVE STUDY; FLOW CYTOMETRY; GENE; GENE TRANSFER; GENETIC TRANSCRIPTION; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOMA; METABOLISM; METHODOLOGY; PATHOLOGY; POLYMERASE CHAIN REACTION;

ANIMAL; ANTIGEN PRESENTATION; CELL DIVISION; CHICKENS; COMPARATIVE STUDY; DENDRITIC CELLS; DNA PRIMERS; ELECTROPORATION; FEMALE; FLOW CYTOMETRY; GENE TRANSFER TECHNIQUES; GENES, MHC CLASS I; GENES, MHC CLASS II; HUMAN; LUMINESCENT PROTEINS; LYMPHOCYTE ACTIVATION; LYMPHOMA; MICE; MICE, INBRED C57BL; OVALBUMIN; PEPTIDE FRAGMENTS; POLYMERASE CHAIN REACTION; RECEPTOR, NERVE GROWTH FACTOR; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC; UBIQUITIN; ANIMALS; GREEN FLUORESCENT PROTEINS; HUMANS;

EID: 0036708241     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700499     Document Type: Article

References (73)

1. The dendritic cell system and its role in immunogenicity
2. Dendritic cells and the control of immunity
3. The cell biology of antigen presentation in dendritic cells
4. Dendritic cells in cancer immunotherapy
5. The dendritic cell and human cancer vaccines
6. Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy?
7. Dendritic cells: A link between innate and adaptive immunity
8. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
9. Induction of antitumor immunity using bone marrow-generated dendritic cells
10. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
11. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines
12. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
13. Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole cell tumor antigens
14. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
15. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
16. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ
17. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
18. + T cell help to elicit antitumor immunity: Implications for the clinical use of dendritic cells
19. + T cell help to elicit protective and therapeutic antitumor immunity
20. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
21. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen
22. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
23. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
24. Human tumor antigens recognized by T lymphocytes
25. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells
26. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro
27. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors
28. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA
29. RNA-transfected dendritic cells in cancer immunotherapy
30. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
31. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA
32. Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: Implications for cervical cancer immunotherapy
33. CD4 T cells and their role in antitumor immune responses
34. The central role of CD4(+) T cells in the antitumor immune response
35. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
36. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
37. + T-helper and a T-killer cell
38. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
39. Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines
40. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors
41. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin
42. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha
43. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: Superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells
44. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells
45. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
46. FACS-optimized mutants of the green fluorescent protein (GFP)
47. Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer
48. The ubiquitin system
49. The N-end rule: Functions, mysteries, uses
50. Universality and structure of the N-end rule
51. Hijacking a chaperone: Manipulation of the MHC class II presentation pathway
52. Sorting signals in the MHC class II invariant chain cytoplasmic tail and transmembrane region determine trafficking to an endocytic processing compartment
53. The MHC class II-associated invariant chain contains two endosomal targeting signals within its cytoplasmic tail
54. Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins
55. C-terminal extension of the MHC class II-associated invariant chain by an antigenic sequence triggers activation of naive T cells
56. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow
57. Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor
58. The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching
59. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody
60. The makings of a tumor rejection antigen
61. Gene therapy with recombinant adenovirus vectors: Evaluation of the host immune response
62. T cell defined tumor antigens
63. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
64. Poxvirus as a vector to transduce human dendritic cells for immunotherapy: Abortive infection but reduced APC function
65. + dendritic cells using recombinant adenovirus suppressed T cell stimulatory capacity
66. Synthetic DNA delivery systems
67. Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes
68. DNA-based immunization by in vivo transfection of dendritic cells
69. Supraoptimal peptide-major histocompatibility complex causes a decrease in bc1-2 levels and allows tumor necrosis factor alpha receptor II-mediated apoptosis of cytotoxic T lymphocytes
70. The induction of virus-specific CTL as a function of increasing epitope expression: Responses rise steadily until excessively high levels of epitope are attained
71. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice
72. Introduction of soluble protein into the class I pathway of antigen processing and presentation
73. Formation and kinetics of MHC class I-ovalbumin peptide complexes on immature and mature murine dendritic cells